« This study identified MAPK14 as a promising disease marker,” they concluded and provided insight into therapeutic targets »
Researchers Identify Novel Biomarker, Therapeuti... - MPN Voice
Researchers Identify Novel Biomarker, Therapeutic Target for Polycythemia Vera
![Manouche profile image](https://images.hu-production.be/avatars/a3b96d3f503b47bbbcb94ae844837ba1_small@2x_100x100.jpg)
![Manouche profile image](https://images.hu-production.be/avatars/a3b96d3f503b47bbbcb94ae844837ba1_small@2x_100x100.jpg)
My understanding here is MAPK14 relates to total levels of Jak2, both mutated and not, and more total Jak2 is a negative.
In this part <<The JAK2 mutation burden was insignificantly higher in the MAPK14-high group compared with the MAPK14-low group (90.5% vs 78.9%; P = .19) which may be due to insufficient samples>>
the P value is high at 0.19. I've started to understand P, it should be less than 0.03 for a statistically important meaning. Their "insufficient" comment matches this idea. I will use this new insight in my thinking on the various other studies we have seen.
This part<<JAK2-homozygous mutation carriers had significantly higher expression of MAPK14 than all other mutation types.>> is consistent with what I've heard, homozyg is a negative, but few tests of ours look for this.
They say it's relevant to PV treatment but <<MAPK14 significantly positively correlated with JAK2 expression in PV and ET patients>> suggests this finding is relevant to ET also.
Hi Manouche,Thank you for sending these updates. Please keep them coming.